Colorado has capped the price of co-pays for insulin, making it the first state to enact a law that combats the soaring costs for the medication that have doubled in the last seven years.
Democratic Gov. Jared Polis signed the bill into law earlier this week, restricting the price for insured patients to co-pays of US$100 a month, according to the Denver Post. The law goes into effect in January.
The skyrocketing cost of insulin has prompted lawmakers, including Congress, to call for price caps and pharmaceutical companies to find ways to drop the cost for patients.
Between 2012 and 2016, prices for insulin nearly doubled, according to a March report from the US House of Representatives. Insulin can cost between US$600 and US$1,000 a month on average.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI